Nuvation Bio price target lowered to $6 from $10 at RBC Capital

RBC Capital lowered its price target on Nuvation Bio (NUVB) to $6 from $10, maintaining an Outperform rating after the company's Ibtrozi received FDA approval for lung cancer treatment. While the firm acknowledges potential challenges in Ibtrozi's launch, including patient identification and competition, it projects peak worldwide revenues of $430 million, citing the drug's favorable profile and improving diagnosis rates; other analysts at H.C. Wainwright and JMP Securities also maintain optimistic ratings, reflecting confidence in Ibtrozi's market potential.

Analysis

Nuvation Bio (NYSE:NUVB) has transitioned into a commercial-stage biotechnology company following the U.S. Food and Drug Administration's full approval for its lung cancer drug, Ibtrozi, indicated for advanced ROS1-positive non-small cell lung cancer. This approval, based on favorable results from the TRUST-I and TRUST-II studies demonstrating high response rates, has led to Ibtrozi's availability in the U.S. at a monthly price of $29,488. Despite this milestone, NUVB stock has declined over 26% in the past week, trading at $1.78. RBC Capital, while maintaining an Outperform rating, lowered its price target from $10.00 to $6.00, citing potential launch challenges such as patient identification difficulties and near-term competitive pressures. However, RBC projects Ibtrozi could achieve $430 million in peak worldwide revenues, believing its favorable profile, long treatment duration, and improving diagnosis rates will drive mid to long-term success, and notes the current valuation "steeply discounts" this new commercial opportunity. Other analysts share a positive outlook, with H.C. Wainwright and JMP Securities maintaining price targets of $10 and $6, respectively. Citizens JMP also reiterated a Market Outperform rating and a $6 price target. Nuvation Bio has launched NuvationConnect to support patient access and plans a conference call to discuss commercialization.

Key Decisions for Investors

• Investors should evaluate Nuvation Bio's current depressed stock price, which analysts suggest significantly undervalues its commercial potential post-Ibtrozi approval, against the backdrop of RBC's revised $6 price target and maintained Outperform rating.
• Monitor early commercialization metrics for Ibtrozi, including patient uptake, physician adoption, and competitive landscape developments, as these will be critical indicators of its ability to meet RBC's $430 million peak revenue projection.
• Consider the divergent analyst price targets ($6-$10) and the recent stock volatility as indicative of both significant upside potential and execution risk associated with the Ibtrozi launch; a long-term perspective may be necessary to realize the drug's projected value.